

STAY CURRENT with FDA-Approved Immunotherapy Treatments from your Office or Home

NEW HAVEN, CONN., LIVE VIRTUAL ACI PROGRAM INFORMATION

Wednesday, Oct. 28, 2020
3–8:30 p.m. EDT

FREE for healthcare professionals, students, patients and patient advocates, the Society for Immunotherapy of Cancer (SITC) Advances in Cancer Immunotherapy™ (ACI) programs are CME-, CNE-, CPE- and MOC-certified and presented by local authorities in tumor immunology and cancer immunotherapy.

NEW HAVEN, CONN., LIVE VIRTUAL ACI PROGRAM TAKEAWAYS

In addition to networking with fellow colleagues, highlights of the program include:

- Interactive, virtual setting to connect with local faculty and organizers
- Learning how to treat patients with FDA-approved immunotherapies
- A deep dive into identifying and managing irAEs
- COVID-19 considerations from the speakers' direct experience
- Interpreting new clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines

Attendees will be able to connect with regional immunotherapy experts during these interactive virtual programs, in subsequent quarterly webinars and through a dedicated SITC CONNECT online community.

All healthcare professionals in the clinical setting, students, patients and patient advocates participate for FREE! For more information or to register for the New Haven, Conn., virtual ACI, please visit sitcancer.org/aci/newhaven

ORGANIZERS:

Marianne Davies, DNP, AOCNP – Yale School of Nursing
Roy S. Herbst, MD, PhD – Yale Cancer Center
Mario Sznol, MD – Yale School of Medicine

ACCREDITATION INFORMATION

AMA Credit Designation

This activity has been approved for AMA PRA Category 1 Credit(s)™.

Pharmacist Credit Designation

This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

Nursing Credit Designation

This activity is eligible for ANCC contact hours, see final CNE activity announcement for specific details.

For full accreditation information and to register for this event, please visit:

sitcancer.org/aci/newhaven

REGISTER YOURSELF AND SHARE WITH A COLLEAGUE

to ensure your entire team is up to date on the latest FDA-approved immunotherapy treatments

The 2020–2021 ACI series is jointly provided by the Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.



Postgraduate Institute
for Medicine



Society for Immunotherapy of Cancer



AMERICAN ACADEMY OF
EMERGENCY MEDICINE
CHAMPION OF THE EMERGENCY PHYSICIAN



Association of Community Cancer Centers



Hematology/Oncology
Pharmacy Association

The 2020–2021 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc. and Merck & Co., Inc.